Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages


This content is available also in other languages

February 25, 2003 | Customer News

The LabCD-ADMET System from Tecan

  • Revolutionary microfluidic technology for miniaturized drug discovery assays
  • Increased productivity and reduced costs through prevalidated miniaturized assays
  • High performance applications for cytochrome P450 inhibition assays and serum protein-binding assays

Zurich, Switzerland, 25 February 2003 – The LabCD-ADMET System, which is based on Tecan’s revolutionary centrifugally driven microfluidics platform, the LabCD, is an easy-to-use solution that can perform a wide range of pre-validated drug discovery assays. This walk-away, fully integrated system initially supports important applications such as ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) assays. These include cytochrome P450 inhibition assays for measuring drug-drug interactions and serum protein-binding assays for measuring the binding characteristics of drug compounds at different serum protein-binding sites. Each assay, which includes the reagents, hardware configuration, and software scripts, is previously validated for ease of use.

The LabCD-ADMET System combines microscale fluid paths, reaction chambers, and passive valves on a disposable compact disc operating on one easy-to-use automated platform (Genesis 150). Tecan’s microfluidic technology platform reduces all of the required steps for a wide variety of separation and assay procedures from a macro- to a microscale and integrates them into a single and affordable LabCD device.



The LabCD-ADMET System has been designed to allow users to quickly set up the system, commence applications and proceed with other tasks as the system takes care of the different steps in various drug discovery assays. Unlike other options that use microplates, the LabCD is part of a fully integrated system that performs all fluid-related functions. The system guarantees reliable and consistent results from one location to another and from one assay to the next. Through advanced miniaturization, the LabCD allows users to significantly reduce reagent consumption. Validated assays and data reduction software provide direct access to information that allows the user to quickly select suitable drug candidates.



At the heart of this cost-effective system is the revolutionary LabCD disc. This disc is implemented on the well-proven Genesis 150 platform with the flexibility to handle both LabCD discs and microplates. Detection capabilities for chemistry reactions are performed by the LabCD Ultra detection system.



Controlling the operation of the system are Tecan’s well proven Gemini and Magellan software. For enhanced performance, a user interface shell was developed to provide the unique customer interface requirements for ADMET applications. Data reduction software was developed to help the customer convert assay data directly into information on selecting suitable drug candidates.

Bob Young, President of Tecan Boston, commented: “We are extremely pleased to have introduced the first LabCD-ADMET Systems. These validated miniaturized systems are able to increase productivity and reduce costs for a range of key drug discovery applications. They will bring significant benefits to many researchers in academic, pharmaceutical and biotechnology laboratories. ” 

For more information, please contact :


Product information:

Tecan Group Ltd.
Cornelia Kegele
Manager Marketing Communications and Branding
Tel.: +41 (0)44 922 81 11
Fax: +41 (0)44 922 82 81
e-mail: cornelia.kegele@tecan.com
Internet: www.tecan.com